GlassScriptPhysician profile
Christopher M Malozzi
NPI 1356409320
$1,719.24
in general payments reported to CMS, 2019-2025
27 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $108 · 2021: $62.62 · 2022: $39.65 · 2023: $13.25 · 2024: $274 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $209.60 | 2019-2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $194.06 | 2019-2025 | |
| Boston Scientific Corporation | $167.99 | 2020-2025 | Emblem Mri S-Icd, Cds - Mct/Cem Monitoring, Watchman Flx |
| Janssen Pharmaceuticals, INC | $113.77 | 2019-2021 | |
| Amgen INC. | $100.49 | 2019-2025 | Repatha |
| Philips North America LLC | $95.16 | 2024-2025 | (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Gilead Sciences, INC. | $94.82 | 2019-2024 | |
| Pfizer INC. | $82.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $72.41 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $63.51 | 2019 | |
| Baxter Healthcare | $56.35 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Ge Healthcare | $55.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $54.30 | 2019-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $53.38 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.59 | 2024-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42.92 | 2024 | Jot Dx |
| Bridgebio Pharma, INC. | $40.45 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $35.93 | 2019 | |
| Glaxosmithkline, LLC. | $22.27 | 2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $22.26 | 2025 | Capvaxive, Verquvo |
| Novo Nordisk INC | $19.92 | 2019 | |
| Medtronic Vascular, INC. | $19.49 | 2019 | |
| Akcea Therapeutics, INC. | $19.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.93 | 2019 | |
| Portola Pharmaceuticals, LLC | $13.27 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Malozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.